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A B S T R A C T
Introduction: Current UK guidance for the treatment of intermittent claudication (IC) states that supervised
exercise programmes (SEPs) should be offered as first-line treatment [1], prior to surgical interventions.
However, there is currently a national shortage of dedicated SEPs. It has been suggested that the established
network of UK Cardiac Rehabilitation (CR) programmes could cater for IC patients. This study will investigate
the feasibility of combining IC and CR patients into one SEP, and explore the patient perception's regarding the
treatment programme, to establish whether CR could potentially fill the gap in service provision.
Methods and analysis: Patients diagnosed with IC will be incorporated into a CR programme where they will
exercise alongside patients with coronary artery disease (CAD). Participants will attend a 2-h class, once a week
for a total of 12 weeks. Another group of IC patients will attend an SEP consisting solely of other IC patients
(control group).
Outcome measures: The study will evaluate the feasibility of recruitment, retention, and participant experience of
the intervention as well as physiological outcomes (primary outcome: pain-free walking, and maximal walking
distance; secondary outcomes: physical activity levels, perceived walking ability, and disease-specific quality of
life). Outcomes will be assessed at baseline and on completion of the SEP.
Ethics and dissemination: Ethical approval for this study was obtained from North West- Greater Manchester West
Research Ethics Committee on 13th June 2018 (IRAS ID: 230391). This study is registered with clinicaltrials. gov
(NCT03564080) and conforms to the Declaration of Helsinki. Results will be disseminated via national con-
ferences and published in peer-reviewed journals.
1. Introduction
Peripheral artery disease (PAD) is a progressive disease that occurs
as the result of atherosclerotic plaque formation in the major arteries of
the leg [2]. The prevalence of PAD in the UK population is 12–14% and
it is estimated that 20% of those with a diagnosis of PAD are over 60
[1]. A quarter of patients with PAD experience limiting symptoms that
cause physical disability. The main symptom is intermittent claudica-
tion (IC), which is categorised as exertional pain or discomfort in the
calf, thigh or buttock that is relieved with rest. In 2012, the National
Institute for Health and Clinical Excellence (NICE) issued clinical gui-
dance that recommended patients diagnosed with PAD should be of-
fered a programme of exercise rehabilitation as a first line treatment,
prior to any surgical intervention [1]. This guidance is supported by a
wealth of high quality research over decades showing the positive
impact of exercise therapy on functional capacity and quality of life
[3–7]. The non-invasive treatment option of exercise therapy has been
shown to be as beneficial as bypass surgery, and more successful than
the use of stents, for increasing walking capacity and improving
symptom management [8,9]. Exercise therapy is also the more cost
effective option, as a 12-week programme would cost approximately
£273, while angioplasty would cost £3,867 [10].
The optimal format for exercise therapy is a supervised exercise
programme (SEP). These programmes should last for 12 weeks and
should be supervised by qualified staff (e.g. exercise physiologists or
physiotherapists). Previous research has shown that this format pro-
vides better patient outcomes when compared to non-supervised or
home-based programmes [11]. Unfortunately, the provision of SEPs in
the UK is currently low with only 24% of vascular surgeons having a
facility to refer their patients to Ref. [12]. The main barriers reported
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are lack of financial and logistical resources. This poor service provision
has massive implications for UK patients, as they do not have access to
the optimal, evidence-based intervention. Due to the progression nature
of the disease, many patients will therefore go on to need to receive the
more invasive and costly revascularisation interventions (angioplasty
and bypass surgery). Researchers have proposed that the already es-
tablished CR rehabilitation services could provide a viable option that
would benefit PAD patients [12,13].
The presence of PAD is also a powerful marker of overall cardio-
vascular risk and preventable cardiovascular deaths. There is a 25–30%
increased risk of death within 5 years for those diagnosed with symp-
tomatic PAD, due mainly to myocardial infarction or stroke [14]. This
progression can be significantly reduced by aggressively modifying
cardiovascular risk factors [15] which is a core component of CR
[16,17]. This is further support for CR programmes providing re-
habilitation for PAD patients.
Previous research has highlighted an appropriateness of combining
different disease populations into one SEP [18]. The study combined
heart failure patients with patients with chronic obstructive pulmonary
disease who shared similar symptoms (exertional shortness of breath
and early onset of fatigue) rather than a shared pathophysiology. CAD
and PAD have a shared pathophysiology – atherosclerosis – although
the symptoms present in different ways and the limitations on exercise
are different. The impact of combining CAD and PAD patients into one
group needs to be investigated it is currently unknown whether com-
bined rehabilitation provides additional or in fact less favourable out-
comes when compared to stand-alone programmes. This research aims
to assess the feasibility of combining the two groups into one re-
habilitation setting to provide support for a full-scale RCT.
In clinical settings such as in the NHS, exploring the views and
experiences of the service users to gain greater understanding has been
shown to improve service provision and subsequently patient uptake
[19]. There is a current gap in literature into patient's perceptions and
opinions of combined rehabilitation. Indeed, there has been little re-
search to date into the perceptions of PAD patients regarding any form
of SEP. This study will therefore utilise a mixed methods design, with
qualitative investigation into the experiences of the patients following
completion of the SEP (see Fig. 1).
2. Methods
2.1. Study setting
This feasibility study will take place in two SEP rehabilitation de-
partments in two NHS Trusts: Manchester Foundation Trust (MFT) and
Salford Royal NHS Foundation Trust (SRFT).
The programme at MFT is a 12-week vascular specific programme,
offering exercise and education to PAD patients diagnosed with IC. This
site will recruit PAD patients and will act as the control group (referred
to as Group 1), as supervised exercise is currently the recommended
standard treatment for PAD patients.
The programme at SRFT is a 12-week Cardiovascular Rehabilitation
programme of exercise and education. This site will recruit both PAD
and CAD patients for the intervention groups (referred to as Group 2
and Group 3, respectively). Both programmes have been running for
over 15 years and follow the recommended guidance for PAD and CR
exercise delivery – NICE [1] and BACPR [17] respectively.
Outcomes will be measured at baseline (pre-rehab) and upon com-
pletion of the SEP (post-rehab). All patients will be invited to partici-
pate in focus groups (post-rehab) in order to investigate their percep-
tions and experiences of the SEP they attended.
2.2. Ethical approval
As this study involves NHS patients, prior approval was obtained
from the North West- Greater Manchester West Research Ethics
Committee on 13th June 2018 (IRAS ID: 230391). This study has also
been registered with clinicaltrials.gov (NCT03564080) and conforms to
the Declaration of Helsinki.
2.3. Study design
There will be 3 arms to this study: a PAD group that is incorporated
in to the CR group (intervention arm 1), the CAD group that currently
make up the Cardiac Rehabilitation referred patients (intervention arm
2), and the stand-alone PAD group (control arm); (see Fig. 2). In order
to generate sufficient data 34 patients will be recruited to each group
with an aim to achieve 17 completers from each group. This is due to an
expectation of high dropout rate for both PAD and CAD programmes
seen at a national level [12,17]. The total recruited will therefore be
102 subjects, to gain 51 completers totally (17 per group).
3. Participants
3.1. Intervention groups
PAD patients (Group 2) will be identified by the vascular specialist
teams (surgeons, nurses and podiatrists) and asked if they wish to take
part in the study. These participants will be invited to participate in the
study during the face-to-face consultation with their specialist, or a
telephone consultation. Potential participants will have approximately
2 weeks to consider enrolling in the research study. Participation will
be on a voluntary basis. Simultaneously, an age-matched group of CAD
patients (Group 3) will be recruited to the combined programme at
SRFT to assess the impact of combined SEP on CAD patients. These
participants will be identified by the Cardiac Rehabilitation Specialist
Nurses at SRFT upon referral to the CR SEP and will have the same 2-
week period to decide about enrolling.
The CAD patient's outcome measures of physical fitness and quality
of life will be compared to the National Audit of Cardiac Rehabilitation
(NACR) as it is outside of the scope of this investigation to have a CAD
only control group. Physical fitness will be measured using the incre-
mental shuttle walk test (ISWT) and quality of life using the Hospital
anxiety and Depression scale. The NACR data is compiled annually and
Fig. 1. Mixed methods study design overview.
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records the national average for these 2 outcome measures. The most
recent year's audit results will be used for comparison.
3.2. Control group or “standard care” group
The control group (Group 1) will consist of PAD patients only and
will take place at an established SEP at MFT. The use of a SEP has been
chosen as the control group or “standard care” group, even though most
patients are unable to receive the standard care in the UK. Other re-
search in this area has had an “exercise advice only” group as control
[13] however, it has been established that SEPs are better than “ex-
ercise advice only” as a treatment option [11]. It has therefore been
considered that it would be unethical for some participants to be
missing out on the recommended SEP treatment.
3.3. Informed consent
In order to gain informed consent from prospective participants, the
content and layout will be described verbally to prospective partici-
pants, along with an easy-to-read leaflet/letter with full description of
the study (Participant Information Sheet). To avoid any risk of coercion,
it will be explicitly stated that they have the right to withdraw from the
study at any point, and that no present or future treatment will be af-
fected by enrolling or not enrolling on the study as per Good Clinical
Practice guidance [20]. All documents will be available in large print if
required.
3.4. Sample size
The sample size of this investigation has been guided by a study by
Evans et al. [18], which investigated the suitability of combining two
Fig. 2. Flowchart of study. This shows the outline of the 12-week study with the 3 groups involved.
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different patient groups (heart failure and chronic obstructive pul-
monary disorder) into one rehabilitation programme. The primary
outcome measured by Evan's et al. [18], was functional capacity, and a
secondary outcome was disease-specific quality of life which matches
two of the main outcomes of this proposed study. The sample size from
Evans et al. [18], has therefore been used in deciding the sample size
for this proposed study. Evans et al. [18], found that 17 participants
were required in each group for their outcome measures to reach sig-
nificance level. Due to the statistically significant findings of Evans
et al. [18], using their sample size as guidance will hopefully allow the
calculation of the required sample size to power a full RCT from the
pilot data.
4. Inclusion and exclusion criteria
4.1. General criteria
As part of this study participants will be required to wear an activity
monitor, the activPAL3 (PAL Technologies Ltd, Glasgow, UK), on the
first week and last week of the 12-week study. The activity monitor will
be kept in place by a medical dressing (e.g. Tegederm®, PAL Stickie®).
People with an existing skin condition such as psoriasis or eczema that
would be affected by the application of a medical dressing will be ex-
cluded from the study.
All participants will be screened prior to commencing their SEP to
ensure they are suitable to take part. The American College of Sports
Medicine's Contraindications for Outpatient Cardiac Rehabilitation will
be used for this screening process [21].
All participants must be able to start the Graded Treadmill Test
(walking speed of 3.2kph, 2mph, 0% gradient). If they are unable to
walk at this pace they will be excluded from the study.
All participants must be able to engage in the exercises prescribed in
the programme (see Supervised Exercise Programme outline below).
No participant will be excluded due to age or gender.
4.2. Inclusion criteria – PAD patients
All patients recruited will have had a recent diagnosis (0–12
months) of PAD made by either a vascular surgeon, vascular specialist
nurse or specialist podiatrist.
4.3. Exclusion criteria – PAD patients
Any patient who has had previous intervention for PAD e.g. balloon
angioplasty, stent, bypass or medication, or who have previously
completed an SEP will be excluded from the study. This is due to the
possibility of previous interventions having an impact on patient per-
ceptions.
Participants who are on vasodilatory medication for PAD (e.g.
naftidrofuryl oxalate) will also be excluded from the study as this can
increase symptom management and improve functional capacity.
Participants who start vasodilatory medication during the study will
also be removed.
Any PAD patient who also has a recent diagnosis of CAD (within the
past 12 months) or have current symptoms of CAD will be excluded
from this study, as the investigation is looking at the specific im-
provements in PAD, rather than improvement in CAD-related symptom
management.
Patients with chronic heart failure (CHF) will be excluded from this
study as the focus is comparing CAD with PAD. The presence of CHF
will be identified by review of past medical history (e.g. echocardio-
gram, under care of HF specialist team).
4.4. Inclusion criteria – CAD patients
All patients recruited to the CR group will have had a recent
diagnosis (0–12 months) of CAD (angina, myocardial infarction (MI), or
coronary artery bypass graft (CABG). Although HF patients are ex-
cluded from the PAD group, patients with HF where ischaemic heart
disease is the primary cause (i.e. ischaemic cardiomyopathy) will be
included in the study, as the cause of their heart condition is CAD.
4.5. Exclusion criteria – CAD patients
Any CAD patient who has had a previous diagnosis of PAD will be
excluded from the study, as their exercise may be limited by PAD
symptoms (i.e. intermittent claudication) rather than the cardiac con-
dition. Any improvement in exercise capacity may therefore be con-
founded by improvements in PAD symptoms [22].
Any participant who has unstable CAD (e.g. unstable angina) will be
excluded from the study as this is a contraindication partaking in
structured exercise programme [16,23].
5. Initial assessment
All participants will be fully assessed prior to starting their 12-week
SEP. This assessment is a standard part of the SEP process where a range
of standard clinical measures are recorded (e.g. resting BP, BMI, and
waist circumference). This will be conducted by one of the rehabilita-
tion team members. All outcome measures will be taken prior to the
patients starting their SEP and repeated upon completion of the pro-
gramme. A summary of all outcome measures is shown in Table 1.
5.1. Outcome measures
The following items are the outcome measures that will be recorded.
The PAD-specific tests have been recommended by the TransAtlantic
Inter-Society Consensus (TASC) Working Group for the Management of
PAD [2]. The others are standard outcomes measures recommended by
the British Association of Cardiovascular Prevention and Rehabilitation
(BACPR) [16].
5.1.1. Primary outcome measures
5.1.1.1. Treadmill test. The Gardner-Skinner Protocol [24] will be used
during this study to assess walking distance, peak walking speed and
functional capacity. The Gardner-Skinner is a standardised graded
protocol functional exercise test (FET) that is commonly used
Table 1
This table provides a summary of quantitative outcome measures and the time-
point at which they will be recorded.
Quantities subjected to post hoc analysis
Quantity Time of measure (weeks)
Demographic
Sex (M/F) BL
Age (years) BL
Clinical
Blood Pressure (mmHg) BL, 12 weeks
Resting Heart rate (bpm) BL, 12 weeks
Height (m), Weight (kg), BMI(kg.m2) BL, 12 weeks
Waist circumference (cm) BL, 12 weeks
Medication BL, 12 weeks
Physical Funtioning
Graded Treadmill Test (GTT) BL, 12 weeks
7-day activity monitoring BL, 12 weeks
Questionnaires
VascuQol (PAD only group) BL, 12 weeks
Hospital Anxiety and Depression Scale (HADS) BL, 12 weeks
Walking Impairment Questnnaires (WIQ) BL, 12 weeks
BL, Baseline; PAD, peripheral artery disease.
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throughout PAD exercise rehabilitation programmes. The treadmill
protocol is as follows:
• Treadmill speed is held constant at 2 mph (3.2. kph)
• Treadmill grade begins at 0% and increases 2% every 2min
For PAD patients, the FET will also establish the initial claudication
distance (ICD) and maximal-claudication distance (MWD) using a IC
pain scale (Fig. 3). ICD is the point at which initial symptoms of IC are
experience (1 out of 4 on the pain scale), and MWD is the point at which
the patient can no longer walk (4 out of 4 on the pain scale).
5.1.2. Secondary outcome measures
5.1.2.1. Walking behaviour and physical activity. Walking behaviour and
physical activity will be recorded by an activPAL® activity monitor (as
used in Clarke et al., 2012) [26] to quantify free-living walking. Data
from the activPAL classifies activities into sedentary, standing and
stride events. Consecutive stride events are combined to give walking
events. The output has been validated for classification of sedentary,
upright, standing and walking activities in a range of populations
including older adults and patients with IC [25–28]. Baseline activity
will be recorded for a 7-day period prior to starting the SEP. During the
week prior to completing the SEP, participants will record another 7-
day period of activity. The outcome data recorded will include steps per
day, step cadence, and sedentary time.
The activPAL® will be attached to the front of the thigh using a
medical grade waterproof dressing. It weighs 15 g.
5.1.3. Quality of life measures
5.1.3.1. Hospital anxiety and depression scale (HADS) questionnaire. This
is a 14-item questionnaire with 7 questions measuring anxiety and 7
questions measuring depression levels. This is a commonly used in
clinical settings and is a standard questionnaire used in Cardiac Rehab
departments [16,23,29]. It takes on average 5min to complete this
questionnaire, and will be completed by the participant on their own.
5.1.3.2. King's college vascular quality of life (Vascu-QoL) questionnaire
(PAD-specific). This is a 25-item disease-specific quality of life
questionnaire that has 5 domains (pain, symptoms, activities, social
and emotional) and has been widely used in PAD research [30,31].
Disease-specific quality of life measures are recommended by TASC
(2007) [2] in combination with generic questionnaires (such as HADs)
as they are more sensitive to change in specific symptoms that are
related to the condition. This questionnaire takes on average 10min to
complete, and will be completed by the participant on their own.
5.1.3.3. Walking impairment questionnaire (WIQ). This is a PAD disease-
specific questionnaire assessing the perceived impact of claudication
symptoms on the individual being measured. This is a commonly used
questionnaire in PAD research since its development by Regensteiner
et al. [32], and is recommended by TASC (2007) [2] to assess patient
perceived symptoms. It takes on average 5min to complete and will be
completed as part of the initial assessment.
5.2. Supervised exercise programme outline
5.2.1. The programme
Patients from all groups will attend a 2-h session once a week, for
12-weeks. This will involve a 1-h supervised exercise session, followed
by an education session. Each session will start with a pre-screening
interview to confirm suitability to exercise that day. The exercise will
start with a warm up period lasting 5–10min for PAD patient, and
10–15min for CAD participants. The prolonged warm up period for
participants with CAD is required to comply with national guidance
[23], due to the risk of developing warm up angina in this population.
This will be followed by a 20–30min conditioning phase, and a 10-min
cool-down. Each participant will have to successfully complete at least
8 of the 12 sessions for the programme to be considered as being
completed.
5.2.1.1. PAD specific exercise. The conditioning phase for the PADs
patients at both hospital programmes will involve completion of a
circuit of exercises designed to bring on claudication within 3–4min.
Participants are encouraged to exercise to near-maximal claudication
pain, and then rest until the pain has subsided before starting the next
exercise. Participants will use the 0–4 scale to rate the claudication pain
experienced during exercise (Fig. 4), with the aim of reaching 3 to 4 on
the scale before starting the rest period. Rehabilitation staff will also
monitor participants heart rate using Polar® FT2 heart rate monitors
(Polar Electro, Kempele, Finland) to ensure that they do not exceed
80% heart rate reserve. This is accordance with the AACVPR [33] and
NICE [1] recommendations and will ensure safe and effective exercise.
The exercises included in the circuit are:
• Treadmill walking
• Heel raises
• Trampette walking/jogging
• Sit to stands
• Toe-walking
• Step ups
5.2.1.2. CAD specific exercise. The conditioning phase for CAD patients
will consist of the same circuit of cardiovascular exercises as the PAD
Fig. 3. Contraindications for outpatient cardiac rehabilitation - american col-
lege of sports medicine [21].
Fig. 4. This shows the Intermittent Claudication Rating Scale which will be
used by patients to grade the amount of claudication pain they experience
during the GTT and SEP. Taken from ACCPVR Guidelines for Cardiac
Rehabilitation and Secondary Prevention Programs (2013).
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group, however this group will exercise symptom-free (i.e. without
chest pain or discomfort). Participants will be given an initial exercise
prescription which details the amount of time spent on the
cardiovascular exercise (ranging from 1 to 5min), which is followed
by 1min of active recovery (marching on the spot with performing a
light resistance exercise e.g. biceps curl). During this interval-based
exercise circuit, CAD patients will be closely monitored by staff using
Polar® FT2 heart rate monitors (Polar Electro, Kempele, Finland) to
ensure patients do not exceed their individually prescribed heart rate
ranges (between 40 and 70% heart rate reserve). The 6–20 Rating of
Perceived Exertion (RPE) scale [34] will also be used to ensure safe and
effect exercise throughout. This complies with the standard cardiac
rehabilitation programme exercise guidance set by the BACPR [16] and
Association of Chartered Physiotherapist working in Cardiac
Rehabilitation (ACPICR) [23].
5.2.1.2.1. Physical activity and exercise advice. As participants
attend each exercise programme only once a week, the rehabilitation
team will provide guidance and encouragement for patients to keep
active outside of the sessions. Patients will be given pedometers to use
and weekly activity goals will be set and reviewed each week by a
member of the rehabilitation team to assess progression. These goals
will be individualised to each patient so that they are progressive and
achievable. An example of a goal could be increasing daily step count
by 500 steps.
5.2.1.2.2. Patient education. Following each of the 12 exercise
sessions, all patients will be invited to attend education sessions. The
sessions are based on the clinical guidance from NICE [1]
recommending patients are educated on the importance of lifestyle
interventions including:
• aggressive lipid modification and statin therapy
• smoking cessation
• diet, weight management and exercise
• the prevention, diagnosis and management of diabetes
• the prevention, diagnosis and management of high blood pressure
• antiplatelet therapy
6. Qualitative post-intervention study
Upon completion of the 12-week supervised exercise programme,
participants will be invited to attend focus groups to explore their
thoughts and concerns about the intervention (Fig. 1). Themes will be
constructed from the data to give insight into the experiences of the
different participant groups. As participation is important for re-
habilitation departments, it is essential to include the participants'
perspective in the evaluation of the treatment programme.
6.1. Data analysis
6.1.1. Quantitative data
The primary outcome data of pain-free and maximal walking
distances will be tested for normal distribution. Statistical analysis
software (IBM SPSS Statistics 24®) will then be used to assess for sig-
nificant differences between the groups pre and post-treatment. Within
groups and between group differences in exercise capacity will be
analysed using a factorial ANOVA to compare the difference in the le-
vels of improvement between groups. Wilcoxon tests will be used to
analyse within group differences in the quality of life questionnaire
data. Between group differences will be analysed using Mann-Whitney
tests.
The CAD group will also be compared to the National Audit of
Cardiac Rehabilitation (NACR) data to assess the impact on the CAD
group performance against expected national levels (physical fitness
and quality of life).
The effect sizes will be calculated using the Cohen's d so that the
results can be compared to other studies.
6.1.2. Qualitative data
The analysis will be influenced by Braun & Clarke's [35] six phases
of thematic analysis as described in Table 2.
The results of both the quantitative data analysis and the thematic
analysis from the focus groups will then be used to draw conclusions
about the effectiveness of the treatment options.
6.1.2.1. Dissemination and impact. Upon completion the study results
will be published in peer-reviewed journals and presented at national
conferences and to patient groups.
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